Physician profile
Kristin E Nesburn
NPI 1003827056
$2,763.22
in general payments reported to CMS, 2019-2025
21 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $278 · 2021: $289 · 2022: $300 · 2023: $122 · 2024: $501 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Travel and Lodging: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.60 |
| Travel and Lodging | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $457.37 | 2019-2025 | |
| Abbvie INC. | $297.22 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $252.03 | 2019-2021 | |
| Allergan, INC. | $204.50 | 2020-2022 | |
| Glaukos Corporation | $193.83 | 2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $169.94 | 2019-2021 | |
| Amgen INC. | $164.74 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $157.87 | 2022-2024 | Tyrvaya |
| Rxsight INC | $155.89 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $132.94 | 2023-2025 | Xiidra, Miebo |
| Alcon Vision LLC | $124.03 | 2024-2025 | Hydrus Microstent, Tryptyr, Rocklatan |
| Dompe US, INC. | $123.83 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.63 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $68.34 | 2021 | |
| Sight Sciences, INC. | $68.17 | 2020-2024 | Omni Surgical System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $24.64 | 2019 | |
| Optos, INC. | $23.91 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.88 | 2019 | |
| Horizon Therapeutics Plc | $17.82 | 2019 | |
| Shire North American Group INC | $17.27 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Nesburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.